Ulrich Von Adrian
Corporate Officer/Principal at Morphic Therapeutic, Inc.
Network origin in Ulrich Von Adrian first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.
16
| Subsidiary | Biotechnology | 16 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Ulrich Von Adrian via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chairman Chief Executive Officer Comptroller/Controller/Auditor Director/Board Member Director/Board Member General Counsel Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Director/Board Member | |
| Bentley University | College/University | Undergraduate Degree Undergraduate Degree | |
| TRANSLATE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member Director/Board Member | |
| KRONOS BIO, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Undergraduate Degree Graduate Degree | |
Tectonic Therapeutic, Inc.
 Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Institute For Protein Innovation, Inc.
 Institute For Protein Innovation, Inc. Miscellaneous Commercial ServicesCommercial Services Institute For Protein Innovation, Inc. is a non-profit company that focuses on enhancing the potential of recombinant antibodies. The company is based in Boston, MA. The company uses sophisticated yeast display technology to generate synthetic, recombinant antibodies. The company was founded by Andrew Kruse, Timothy A. Springer. Kenneth Fasman has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Dewpoint Therapeutics, Inc.
 Dewpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| SCHOLAR ROCK HOLDING CORPORATION | Biotechnology | Founder Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
| University of Aarhus | College/University | Graduate Degree | |
| DYAX CORP. | Pharmaceuticals: Major | Chief Executive Officer | |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Pharmaceuticals: Major | Corporate Officer/Principal | |
BioVentures Investors
 BioVentures Investors Investment ManagersFinance BioVentures Investors (BioVentures) is a venture capital firm founded in 1997 by Peter J. Feinstein and Marc E. Goldberg. The firm is headquartered in Wellesley, Massachusetts. | Investment Managers | Private Equity Investor | |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member | |
| BAXTER INTERNATIONAL INC. | Medical Specialties | Corporate Officer/Principal | |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Miscellaneous Commercial Services | Chairman | |
Apeiron Partners LLC
 Apeiron Partners LLC Investment ManagersFinance Apeiron Partners LLC provides investment advice. The private company is based in Boston, MA. The company was founded by Jeffrey D. Wager. | Investment Managers | Corporate Officer/Principal | |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Alpha-Beta Technology, Inc.
 Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Components | Chairman | |
Phytera, Inc.
 Phytera, Inc. Miscellaneous Commercial ServicesCommercial Services Phytera, Inc. develops plant-based and marine-based pharmaceuticals. The company is headquartered in Shrewsbury, MA. | Miscellaneous Commercial Services | President | |
| GENERATION BIO CO. | Pharmaceuticals: Major | Director/Board Member | |
| McGill University | College/University | Doctorate Degree | |
Fusion MPHC Group, Inc. (Delaware)
 Fusion MPHC Group, Inc. (Delaware) Specialty TelecommunicationsCommunications Fusion MPHC Group, Inc. provides integrated voice and data communication services. It offers broadband Internet access service for small and mid-sized businesses; business phone and Internet services; VPN and security services; email and web hosting services; and enterprise solutions. The firm also provides voice over IP, wireless and voice services on a managed national broadband network, wholesale and carrier services. The company is headquartered in DE. | Specialty Telecommunications | Corporate Officer/Principal | |
| DELTAGEN INC. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| PANACEA ACQUISITION CORP. II | Financial Conglomerates | Director/Board Member | |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor | |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Director/Board Member | |
| IKENA ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
| TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Corporate Officer/Principal | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| United States | 43 |
| Denmark | 3 |
| Germany | 3 |
| Cayman Islands | 2 |
| Canada | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 8 |
| Commercial Services | 8 |
| Finance | 8 |
| Electronic Technology | 3 |
Operational
| Director/Board Member | 194 |
| Independent Dir/Board Member | 46 |
| Corporate Officer/Principal | 46 |
| Chief Executive Officer | 18 |
| Founder | 16 |
Most connected contacts
| Insiders | |
|---|---|
| Amir Nashat | 51 |
| Martin Edwards | 38 |
| Otello Stampacchia | 37 |
| Nilesh Kumar | 26 |
| Susannah Gray | 20 |
| Timothy Springer | 19 |
| Joseph Slattery | 18 |
| Vikas Goyal | 16 |
| Mark Murcko | 16 |
| Gustav Christensen | 14 |
| Praveen Tipirneni | 13 |
| Norbert W. Bischofberger | 12 |
| Marc Schegerin | 11 |
| Robert Farrell | 7 |
| Brihad Abhyankar | 7 |
- Stock Market
- Insiders
- Ulrich Von Adrian
- Company connections
